You don’t get rid of the management when they ar
Post# of 153771
(Total Views: 880)
Posted On: 06/28/2021 1:12:38 PM
You don’t get rid of the management when they are trying to lock up a bunch more patents. How ignorant can you be?
Did you not hear in the last web call what the plan is and the importance of this plan to our investment? If we stop the direction or the management now when they are trying to establish more patents. That would be a serious set back and could topple our drug and our investment. There is already CCR5 antagonist on the market and we need to lock up the use of these patents for the individual uses before the other drug companies do. The importance of this is beyond any benefit you believe a change in management would mean. Even though I disagree with a management change. If we were to change the management it could cripple our future and delay everything or lose everything with just a delay in time. We are not the only CCR5 antagonist being used and researched. The winner just may be time related.
You my friend are blind to the fact that everything is going just as it should and the 13d group would or could NOT offer anything better. So you should be careful what you are asking for because not only has Nader got us to this point. His leadership just might be essential to our future and locking up as many patents as we can before the others catch up to our trial knowledge. You see… we are on a tear right now discovering just how Leronlimab works for each individual indications because dosing and time between dosing is being recognized and this is where we will be able to patent our success of our knowledge from our trials. It’s plain to see that Leronlimab works different for each indication as a immune modulator.
You have to realize that our management isn’t releasing all they know for good reason… it must be killing Nader to not tell us everything that is being learned. But patents will tell the real story. Prepare for greatness of Leronlimab. Patents are the most important thing that we need right now. I am Thankful that the current management is pushing that envelope. We all should be thankful.
Did you not hear in the last web call what the plan is and the importance of this plan to our investment? If we stop the direction or the management now when they are trying to establish more patents. That would be a serious set back and could topple our drug and our investment. There is already CCR5 antagonist on the market and we need to lock up the use of these patents for the individual uses before the other drug companies do. The importance of this is beyond any benefit you believe a change in management would mean. Even though I disagree with a management change. If we were to change the management it could cripple our future and delay everything or lose everything with just a delay in time. We are not the only CCR5 antagonist being used and researched. The winner just may be time related.
You my friend are blind to the fact that everything is going just as it should and the 13d group would or could NOT offer anything better. So you should be careful what you are asking for because not only has Nader got us to this point. His leadership just might be essential to our future and locking up as many patents as we can before the others catch up to our trial knowledge. You see… we are on a tear right now discovering just how Leronlimab works for each individual indications because dosing and time between dosing is being recognized and this is where we will be able to patent our success of our knowledge from our trials. It’s plain to see that Leronlimab works different for each indication as a immune modulator.
You have to realize that our management isn’t releasing all they know for good reason… it must be killing Nader to not tell us everything that is being learned. But patents will tell the real story. Prepare for greatness of Leronlimab. Patents are the most important thing that we need right now. I am Thankful that the current management is pushing that envelope. We all should be thankful.
(14)
(3)